Clinical Trials at
Houston Mind & Brain
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26-week treatment period in patients with schizophrenia (CONNEX-1)
Can Research Change the Way People Live with Schizophrenia?
We’re looking for people to join a research study who may be struggling with memory and thinking skills due to schizophrenia. Find out more about this study and see if you qualify. For more information, please contact our study coordinator, Hannah Kelly, at 832-356-2421 or hannah.kelly@houstonmindandbrain.com
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm
Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects with Major Depressive Disorder
Are you experiencing a low or depressed mood and a decreased interest in pleasurable activities? Do you have feelings of guilt or worthlessness, lack of energy, or poor concentration?
This research study is being conducted to assess the effectiveness, safety, and tolerability of centanafadine once-daily extended-release capsules for the possible treatment of adult participants with MDD who have reported inadequate response to at least 1 but no more than 3 treatments for depression in their current major depressive episode (MDE). This research study will test the hypothesis that centanafadine as monotherapy or in addition to SSRI (escitalopram) will lead to greater overall effectiveness in the possible treatment of MDD when compared to escitalopram alone or to placebo. For more information, please contact our study coordinator, Hannah Kelly, at 832-356-2421 or hannah.kelly@houstonmindandbrain.com
For more information on either study, please fill out this form:
